**Core Concept**
Deprescription of PPIs involves tapering or discontinuing proton pump inhibitors in patients who are at low risk for gastrointestinal complications. This approach aims to reduce the risk of adverse effects associated with long-term PPI use, such as osteoporosis, vitamin B12 deficiency, and Clostridioides difficile infection.

**Why the Correct Answer is Right**
Deprescription of PPIs can be done in patients who are at low risk for gastrointestinal complications, such as those with non-erosive reflux disease or those who have undergone endoscopic eradication of Helicobacter pylori infection. However, patients with conditions such as Zollinger-Ellison syndrome, severe gastroesophageal reflux disease (GERD), or those with a history of gastrointestinal bleeding may require continued PPI therapy. In these cases, deprescription may lead to a relapse of symptoms or worsening of the underlying condition.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not provided, so we cannot evaluate it.
* **Option B:** This option is not provided, so we cannot evaluate it.
* **Option C:** This option is not provided, so we cannot evaluate it.
* **Option D:** This option is not provided, so we cannot evaluate it.

**Clinical Pearl / High-Yield Fact**
When deprescribing PPIs, it is essential to carefully evaluate the patient's risk factors for gastrointestinal complications and to gradually taper the medication to minimize the risk of relapse.

**Correct Answer: A.**